Connect with us

News

BitOoda Launches Hashpower Contract

gbafNews28

BitOoda Digital, LLC (BitOoda) today announced it successfully executed the first BitOoda Hash„¢ contract. The initial contract was between Coinmint LLC (Coinmint), operator of the largest digital currency data center in North America, and an undisclosed buyer. The contract is a standardized agreement for the purchase and sale of large blocks of physically-delivered Bitcoin hashpower “ computing power utilized to run the Bitcoin mining algorithm “ from industrial cryptocurrency mining operations. Tagomi Trading, LLC (Tagomi) will act as the calculation and settlement agent for the buyer, handling the delivery, custody, and conversion of the BTC mined with the purchased hashpower.

Sam Doctor, Chief Strategist at BitOoda, said: Institutional market participants demand professional products and solutions. This contract, built with an emphasis on transparency and accountability, is a critical step forward in the evolution of hash as a fungible commodity and the development of a robust hashpower market. Buyers accept price and difficulty risk in exchange for the opportunity to own Bitcoin at a discount to spot, while selling miners lock in their profits and receive an alternate source of capital to fund growth.

This first-of-its-kind product optimizes the settlement and delivery process, and enables seamless transacting of hashpower in the over-the-counter markets. BitOoda aims to scale the operation with its partners Coinmint and Tagomi and establish a frictionless end-to-end solution for global hashpower merchants.

“We’re excited to be working with BitOoda and top industry participants in facilitating more advanced products, and acting as the trade execution and settlement layer for them,” said Marc Bhargava, Co-founder and President of Tagomi.

Ashton Soniat, CEO of Coinmint, said: At Coinmint, we pride ourselves on being at the cutting edge of the mining space. This contract represents the next step in creating a transparent and liquid hashpower market in North America.

BitOoda plans to introduce the product worldwide alongside its proprietary suite of mining services, which also includes the previously released BitOoda Difficulty„¢ swap. To learn more about BitOodas offerings, please email [email protected].

About BitOoda

BitOoda Holdings, LLC is a global financial services platform based in Jersey City, NJ. Its mission is to accelerate the global adoption of transformational technologies by promoting transparent and efficient marketplaces, through innovative and professional capital markets solutions. BitOoda Holdings, LLCs subsidiaries include Ooda Commodities LLC, a CFTC/NFA-registered Introducing Broker; BitOoda Technologies LLC, an SEC/FINRA-registered Broker-Dealer; and BitOoda Digital LLC, which has applied for a NY DFS BitLicense. BitOoda Hash and BitOoda Difficulty are trademarks of BitOoda Holdings, LLC. For more information please visit www.bitooda.io.

Timothy Kelly

[email protected]

+1 (646) 484-1073

News

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

gbafNews28

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose (MTD) for continuous daily dosing. The data are being presented in a poster session at the 32nd EORTC-NCI-AACR Symposium.

These early findings from our Phase 1 trial of SY-5609 reinforce our conviction in CDK7 inhibition as a potentially transformative targeted approach for difficult-to-treat cancers, said David A. Roth, M.D., Chief Medical Officer of Syros. As we move forward in this trial, we are committed to fully exploring the potential of SY-5609. To that end, we opened the trial to pancreatic cancer patients, expanded a cohort to focus on lung cancer patients, and also expanded the combination cohort in treatment-resistant breast cancer patients. Additionally, we opened cohorts evaluating alternate dosing regimens, all with the goal of identifying optimal next steps for pursuing single-agent and combination development opportunities and ultimately delivering the greatest benefit to patients.

Early Data Demonstrate Proof-of-Mechanism at Tolerable Doses

Syros presented initial data from its ongoing Phase 1 multi-center, open-label, dose-escalation study of SY-5609 in patients with advanced breast, colorectal, lung, ovarian or pancreatic cancer, or other solid tumors with Rb pathway alterations. The study also includes a cohort evaluating SY-5609 in combination with fulvestrant in CDK4/6 inhibitor-resistant HR-positive breast cancer patients.

As of August 21, 17 patients had been enrolled in the trial and were eligible for safety, PK and PD analysis. Patients were either treated with continuous daily dosing of single-agent SY-5609 at 1, 3, 4 or 5 mg, or for three weeks on and one week off at 3 mg in combination with fulvestrant. The median age of the patients enrolled in the study was 64. Patients were heavily pretreated with a median of four prior therapies. The MTD for continuous daily dosing was achieved at 3 mg. The data showed that:

  • SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity.
    • Notably, increases in POLR2A in patients treated at 3 mg daily reached levels associated with tumor regressions in preclinical models, as well as with levels of CDK7 target engagement at which a clinical response and apoptosis were observed in a trial of patients treated with a first-generation IV CDK7 inhibitor.
  • SY-5609 demonstrated approximately dose-proportional PK as both a single agent and in combination, minimal accumulation with repeat dosing, and a steady state half-life compatible with once-daily dosing.
  • The majority of adverse events reported with SY-5609 as a single agent were low grade. The most common AEs were nausea, diarrhea, fatigue, platelet count decrease, and vomiting.
  • The safety profile of SY-5609 in combination with fulvestrant was consistent with that of single-agent SY-5609.
  • Five of the 13 patients treated with single-agent SY-5609 were response evaluable, and of those, three achieved stable disease and two had progressive disease; one of the four patients treated in the combination cohort was response evaluable and had progressive disease.

The Phase 1 trial continues to actively enroll patients with select solid tumors, including the recently expanded single-agent cohort in lung cancer patients and combination cohort in breast cancer patients, to further evaluate the 3 mg daily dose in focused patient populations. The trial has also been opened to patients with advanced pancreatic cancer, another tumor type that has demonstrated sensitivity to SY-5609 in preclinical models. Additional cohorts are evaluating alternate regimens, supported by preclinical data showing that intermittent regimens of SY-5609 induced tumor regressions.

Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021. Additional details about the Phase 1 trial of SY-5609 can be found using the identifier NCT04247126 at www.clinicaltrials.gov.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the timing for reporting additional dose-escalation data, including clinical activity data, from the Phase 1 clinical trial of SY-5609, the future expansion of such trial to include additional cohorts and dosing regimens, and the ability of SY-5609 to have a benefit for patients. Moreover, there can be no assurance that the initial clinical data generated to date in the ongoing Phase 1 clinical trial of SY-5609 are predictive of the ability of any cohort of such trial to meet any of its endpoints or to continue comparing favorably with other treatments or treatment regimens. The words ˜˜anticipate, ˜˜believe, ˜˜continue, ˜˜could, ˜˜estimate, ˜˜expect, hope, ˜˜intend, ˜˜may, ˜˜plan, ˜˜potential, ˜˜predict, ˜˜project, ˜˜target, ˜˜should, ˜˜would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros ability to: advance the development of SY-5609 under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of SY-5609; sustain the response rates seen to date with SY-5609; replicate scientific and non-clinical data in clinical trials; successfully establish a patient selection strategy and develop a companion diagnostic test to identify patients most likely to benefit from SY-5609; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption Risk Factors in Syros Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future. In addition, the extent to which the COVID-19 outbreak continues to impact our workforce and our research, supply chain and clinical trial operations activities, and the operations of the third parties on which we rely, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact. Any forward-looking statements contained in this press release speak only as of the date hereof, and Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Media Contact:

Naomi Aoki

Syros Pharmaceuticals

617-283-4298

[email protected]

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

[email protected]

Continue Reading

News

Daiya Healthcare Makes Big Waves in the Aloha State

gbafNews28

Daiya Healthcare, the nations leading provider group in Post-Acute and Long-Term Care Medicine, expanded operations to the Aloha State and has brought along a wave of significantly improved standards of medical care to the Garden Isle of Kauai. The group has brought clinicians specialized in Primary Care, Psychiatry, Palliative Care, and Pain Management to Hawaii. These clinicians provide a higher level of care to the patients they serve in Kauai and throughout the Hawaiian Islands.

Never before have post-acute and long-term care residents in Hawaii had access to primary and specialty care like this, says Brandi Hori-Moises, a Nursing Home Administrator at Regency Kauai Care Center. We have been trying for years to get this level of service for our states most vulnerable population, and the pandemic has taught us how important it is to have high-level medical care in Skilled Nursing Facilities, Brandi adds. Daiya Healthcare began providing services on the island of Kauai last month, and has already positively impacted the re-hospitalization rate for Regency Kauai Care Center. We need them everywhere, says Brandi. I hope to see them on all of the neighbor islands.

Daiya Healthcare expanded services to Hawaii earlier this summer. We are very fortunate to partner with Kauai Care Center and serve the treasured kupuna of Hawaii, says Daiya Healthcares Chief Strategy Officer, Michelle Thompson. The group is looking to greatly expand its program to provide similar services on The Big Island, Oahu, and Maui. Our unique offering is a proven model of success, bringing significant value to our patients and facility partners, commented Daiya Healthcares CEO, Bhupinder Walia. Dr. Walia adds, We are excited to revolutionize medical care in skilled nursing facilities throughout the Hawaiian islands, as we have successfully done on the mainland.

About Daiya Healthcare

Daiya Healthcare is a physician owned multi-specialty provider group offering unparalleled services in post-acute and long-term care centers. Based in Bellevue, Washington, Daiya Healthcare is the nations leader in post-acute and long-term care medicine. They currently serve in over 70 centers throughout Washington, Oregon, Idaho, Hawaii, New Mexico and California. Daiya Healthcare is based on a core value system of Integrity, Compassion, Diversity and Accountability, which is essential to providing an integrated care model to the communities and partners they serve. To learn more about Daiya Healthcare, please visit the company website at www.daiyahealthcare.com.

Michelle Thompson

(425) 410-9514

Continue Reading

News

Restoration Along Oregon’s John Day River at Longview Ranch

gbafNews28

Located along Central Oregons historic Route 19 in Kimberly, Longview Ranch maintains 30,000 stunning acres of diverse landscape. Eight miles of the John Day River flows through the middle of the property, which operates primarily for the purpose of raising grass-fed cattle.

For years, the spring runoffs of the John Day River flowed through the ranch, causing massive flooding along the banks. In an effort to combat this devastation and reestablish vegetation, Longview Ranch implemented a restoration project, including the introduction of a large number of trees and willows. The ranch remains committed to responsible, sustainable practices, and each year invests in the prevention of noxious weeds that could injure the land and its neighboring farms.

Longview Ranchs efforts along the John Day River have produced successful riparian zone restoration and the promotion of a rich, biodiverse habitat.

About Longview Ranch

Located along Central Oregons historic Route 19 in Kimberly, Longview Ranch maintains 30,000 stunning acres of diverse landscape. Eight miles of the John Day River flows through the middle of the property, which operates primarily for the purpose of raising grass-fed cattle. With three tributaries sharing annual steelhead runs, Longview Ranch also manages 25,000 acres of Bureau of Land Management (BLM) grazing grounds and 485 acres of irrigated hay producing land, which is home to 800 mother cows and 50 bulls.

Longview Ranch remains committed to responsible, sustainable land-use practices, and has completed a restoration project along the John Day River to reestablish vegetation. Each year, the property invests in the prevention of noxious weeds that could harm the land at Longview Ranch, as well as its neighboring farms. The ranch also partakes in best practices regarding wildlife, limiting hunting on property and ensuring elk herds have a refuge. Additionally, while the area is not known for large numbers of antelope, in thanks to the integrity of the property, more than 200 does and bucks can be found at Longview Ranch.

Longview Ranch has also has a rich history of giving back to its community, making annual donations to the Grant County 4-H and Union County Chapter of the Rocky Mountain Elk Foundation.

Katie Schoen, [email protected]

 

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News2 hours ago

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety,...

gbafNews28 gbafNews28
News9 hours ago

Daiya Healthcare Makes Big Waves in the Aloha State

Daiya Healthcare, the nations leading provider group in Post-Acute and Long-Term Care Medicine, expanded operations to the Aloha State and...

gbafNews28 gbafNews28
News10 hours ago

Restoration Along Oregon’s John Day River at Longview Ranch

Located along Central Oregons historic Route 19 in Kimberly, Longview Ranch maintains 30,000 stunning acres of diverse landscape. Eight miles...

gbafNews28 gbafNews28
News11 hours ago

Liquid Biopsy Market | COVID-19 Recovery and Growth Opportunities | Technavio

The liquid biopsy market is poised to grow by USD 4.02 billion during 2020-2024, progressing at a CAGR of almost...

gbafNews28 gbafNews28
News11 hours ago

Global dPCR Market- Featuring Avance Biosciences Inc., Becton, Dickinson and Co., and Bio-Rad Laboratories Inc. Among Others

The dPCR market is poised to grow by USD 518.69 million during 2020-2024, progressing at a CAGR of over 24%...

gbafNews28 gbafNews28
News11 hours ago

Potential Sunday/Oct. 25 PSPS Event: Forecasted Highest Winds and Driest Conditions of the Season Mean PG&E May Need to Proactively Turn Off Power for Safety to Approximately 466,000 Customers Across Northern and Central California

Pacific Gas and Electric Companys (PG&E) Emergency Operations Center, Meteorology team and Wildfire Safety Operations Center are working together and...

gbafNews28 gbafNews28
News11 hours ago

Global Phenolic Resin Market with Highlights on the Impact of COVID-19, 2020-2024 | Advantages of Phenolic Resins to Boost Market Growth | Technavio

The phenolic resin market is expected to grow by USD 4.56 billion during 2020-2024, according to Technavio. The report offers...

gbafNews28 gbafNews28
News11 hours ago

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Expedia Group, Inc. On Behalf of Former Investors in Liberty Expedia Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf...

gbafNews28 gbafNews28
News12 hours ago

Facial Recognition Market | Increasing Instances of Identity Theft to Boost the Market Growth | Technavio

The global facial recognition market size is poised to grow by USD 3.35 billion during 2020-2024, progressing at a CAGR...

gbafNews28 gbafNews28
News12 hours ago

IPHA LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Innate Pharma S.A. – IPHA

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of...